European Pharmaceutical Pricing and Reimbursement conference
1. REGISTER BY 30TH JUNE AND RECEIVE A £300 DISCOUNT
SMi present their 17th Annual Conference on...
European Pharmaceutical
Pricing and Reimbursement
Monday 31st October & Tuesday 1st November 2011
Radisson Blu Hotel Basel, Switzerland
KEYNOTE SPEAKERS: OTHER SPEAKERS INCLUDE:
Andrea Rappagliosi Markus Jahn
Vice President, European Government Manager Pricing
Affairs & Head of Brussels Office Novartis Pharma
GlaxoSmithKline Henderson Azevedo
Market Pricing Director Northern &
Peter Kolominsky-Rabas Central Europe and Canada
Director, Interdisciplinary Centre Novartis Pharma
Health Technology Assessment and Jan Posthumus
Public Health Head of Market Access & Market Research
Basilea Pharmaceutica
International Ltd.
Martina Garau
Senior Economist Frank Thoss, Lawyer
Office of Health Economics Strategic Policy Affairs
VFA
Isabel Henkel Elke Hunsche
Director Access & Reimbursement Director, Head of Health Economics &
Johnson & Johnson Medical Pricing
2011 has brought huge changes to the Actelion Pharmaceuticals
healthcare landscape – the global economic
crisis and rising healthcare costs have caused
governments to take cautious approaches CONFERENCE HIGHLIGHTS
towards pricing and reimbursement. With an • Get to grips with the facts and consequences of Germanys AMNOG
essential review of the key challenges and • Debate EU policy challenges in access to medicines in Europe
developments in VBP, AMNOG and other EU • Analyse market access in new emerging markets
policy challenges, SMi's 17th annual European • Understand Value Based Pricing: Principles and practice in the UK
Pharmaceutical Pricing and Reimbursement policy context
• Get up to speed with the latest regulations within P&R
Conference will feature presentations on the
• Discover the value of collaboration in HTA and managed entry
latest P&R issues from the industry’s most
schemes
senior professionals and academics.
PLUS TWO INTERACTIVE POST-CONFERENCE WORKSHOPS
Sponsored by
Wednesday 2nd November 2011, Radisson Blu Hotel Basel, Basel, Switzerland
Workshop A - Market Access in Emerging Markets: Overview of growth
opportunities and key market access challenges in emerging markets
Hosted by Gustav Ando, Director, Healthcare & Pharma, IHS Global Insight, Aparna Krishnan, Manager, Emerging Markets,
Healthcare & Pharma, IHS Global Insight, Ruben Gennero, Research Analyst, Healthcare & Pharma, IHS Global Insight
8.30am - 12.30pm
Workshop B - Cooperation with Payors as a Means for AttainingReimbursement
Hosted by Norbert Jersch, Partner, Roman Rittweger Advisors in Healthcare
1.00pm - 5.00pm
www.smi-online.co.uk/2011europricing.asp
Register online and receive full information on all of SMi’s conferences
Alternatively fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
2. European Pharmaceutical Pricing and Reimbursement
Day One | Monday 31st October 2011 www.smi-online.co.uk
8.30 Registration & coffee ORPHAN DRUGS
9.00 Chairman's opening remarks
Donald Macarthur, Global Pharmaceutical Business Analyst 1.50 Orphan Drug P&R in Europe: Are the payers biting back?
• Situation with approved orphan drugs in EU-5
EU POLICY CHALLENGES
• Vital role of funding
KEYNOTE ADDRESS • What payers won't buy
9.10 EU policy challenges in access to medicines in Europe: the value of
collaboration in HTA and managed entry schemes • How and where HTA limits access
• Assessment and Appraisal: is there a scope for European • Successful company strategies
collaboration in HTA to prove clinical value to governments and
payers? Donald Macarthur, Global Pharmaceutical Business Analyst
• How the new challenges of “valuable innovation” can be addressed
in order to meet priorities in healthcare?
2.30 Orphan Drug Challenges in Europe and Future Opportunities for
• Will Managed Entry Schemes provide a refined tool to address
uncertainties in patients access? Development
• Can stakeholders contribute effectively to the setting of shared
• Critical success factors and challenges
rules?
Andrea Rappagliosi, Vice President, European Government Affairs & • Future opportunities in orphan drug development
Head of Brussels Office, GlaxoSmithKline
Elke Hunsche, Director, Head of Health Economics & Pricing,
KEYNOTE ADDRESS Actelion Pharmaceuticals
9.50 The role of HTA agencies
• HTA expectations in late phase development
• HTA agency policy and practice globally: comparing and contrasting 3.10 Afternoon Tea
different models
• Opportunities for Early Engagement with HTA agencies
Peter Kolominsky-Rabas, Director, Interdisciplinary Centre, Health 3.40 Market Access to Orphan Drugs in Italy
Technology Assessment and Public Health • Mechanisms for “early reimbursement” of orphan drugs
10.30 Morning Coffee • The pricing and reimbursement process for orphan drugs
• Orphan drugs and innovation
AMNOG
Laura Crippa, Director, Market Access and Pricing, Temas S.r.l.
11.00 Pricing in Germany with new AMNOG Unipersonale
• Benefit assessment of launch drugs and in-market brands
• Pricing roadmap after benefit assessment - fixed price or central
price-negotiation 4.20 Change Drivers in pricing and reimbursement practice
• First experiences with the new regulation and outlook • Changing macroeconomic environment – countries under economic
Markus Jahn, Manager Pricing, Novartis Pharma
pressure
11.40 Germanys AMNOG: Facts and consequences • Envolving stakeholder roles – the patient
• Regulation of the German pharmaceutical market before AMNOG
before Jan 1st 2011 • P&R evaluation price setting and reimbursement mechanisms
• AMNOG-process of early benefit assessment and central price- • Increased use of generics and similar - perceptions
negotiations in detail
• Possible consequences for other countries Jorge Wernli, Vice President, Global Pricing and Government Affairs,
Frank Thoss, Lawyer, Strategic Policy Affairs, VFA - German Vifor Pharma
Association of Research-Based Pharmaceutical Companies
12.20 Networking Lunch 5.00 Chairman’s Closing Remarks and Close of Day One
Register online at www.smi-online.co.uk/2011europricing.asp • Alternat
PHARMACEUTICAL FORWARD PLANNER
June 2011 18/19 Pharmaceutical and Clinical Trial Logistics Asia 19/20 COPD: Novel Therapeutics and Management
27/28 RNAi, miRNA, siRNA Pacific (Singapore) Strategies
29/30 Pharmaceutical Portfolio & Product 20/21 Pre Filled Syringes Asia (Singapore) 24/25 Point of Care Diagnostics - Market Opportunities and
Life Cycle Management Technology Trends
29/30 Pharmaceutical Nanotechnology September 2011
29/30 KOL Management and MSL 19/20 Biomarkers in Clinical Trials November 2011
Best Practice in Europe (Munich, Germany) 26/27 Biosimilars and Biobetters 31 Oct/1 Nov European Pharmaceutical Pricing
28/29 KOL Liaison and MSL Best Practice & Reimbursement (Switzerland)
July 2011 16/17 Clinical Trials in CNS
06/07 ADMET October 2011 21/22 Cell Based Assay
06/07 Social Media in the Pharmaceutical Industry 03/04 Managing Partnerships with CROs
11/12 BioBanking 10/11 Pharmaceutical m-Health December 2011
12/13 GP Commissioning 5/6 Cold Chain Distribution
All conferences take place in central London, UK – unless indicated otherwise in brackets
Supported by
3. European Pharmaceutical Pricing and Reimbursement
k/2011europricing.asp Day Two | Tuesday 1st November 2011
8.30 Re- Registration & coffee 12.20 Networking Lunch
9.00 Chairman's opening remarks
Neil Palmer, President and Principal Consultant, PDCI Market 1.50 The patient’s role in market access in public healthcare systems
Access Inc
• Increasing patient choices in an equitable way
ESTABLISHED MARKET OVERVIEW
• Patient-reported outcome measures
KEYNOTE ADDRESS • Achieving maximum levels of patient and market access
9.10 Value based pricing - Principles and practice in the UK policy
context Bertram Haussler, Chairman of the Board of Management, IGES
• Approaches to value base pricing (VBP)
Insitut. Berlin
• Lessons learnt from international experience of VBP
• Introducing VBP in the UK:
- The Department of Health consultation
- How might VBP be implemented and what are the expected 2.30 The access marketing mix for launch products
consequences? • Access marketing for the different stakeholders
Martina Garau, Senior Economist, Office of Health Economics
• Preparation for launch from an access perspective: timelines,
KEYNOTE ADDRESS
tools and techniques
9.50 Market access in European Established Markets
• Overview of key stakeholders in Europe’s established markets Jan Posthumus, Head of Market Access & Market Research, Basilea
• Who are the key agencies in the market
• Understanding HTA regulations in Europe Pharmaceutica International Ltd
Isabel Henkel, MPH, Director Access & Reimbursement, Johnson &
Johnson Medical
3.10 Afternoon Tea
10.30 Morning Coffee
MARKET ACCESS 3.40 Latest regulations within pricing and reimbursement
11.00 Market access in emerging markets • EU initiatives in pricing and reimbursement
• Recent developments and future trends
• Opportunities and threats - a pharmaceutical industry perspective • Risk Sharing Agreements
• Lessons from developed markets • Patient Access Schemes
Henderson Azevedo, Market Pricing Director Northern & Central
Europe and Canada, Novartis Pharma James Killick, Partner, White & Case LLP
11.40 Canadian Market Access Update
• Overview of Canadian health care system and pharmaceutical 4.20 Sweden Market Access update
funding
• Price regulation and the new Patented Medicine Prices Review • Cost-effectiveness and cost utility
Board (PMPRB) guidelines
• What is the value at stake?
• CADTH - Common Drug Review (CDR), pCODR (oncology drugs),
INESSS (Quebec), provincial and private reimbursement schemes • Price analysis for new product candidates
• Implications of the Ontario 25% pricing rule for generics and the
evolution of Product Listing Agreements (PLAs) Jacob Brun, Pricing & Reimbursement Director, AstraZeneca
• Outlook for Canadian pricing & reimbursement
W. Neil Palmer, President & Principal Consultant, PDCI Market
Access Inc. 5.00 Chairman’s Closing Remarks and Close of Conference
tively fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
Sponsored by
SPONSORSHIP AND EXHIBITION OPPORTUNITIES
PDCI Market Access (PDCI) is Canada’s leading SMi offer sponsorship, exhibition, advertising and branding packages,
pharmaceutical pricing and reimbursement uniquely tailored to complement your company’s marketing strategy.
consultancy. Established in 1996, the firm assists Prime networking opportunities exist to entertain, enhance and expand
clients navigate the complex pricing and market your client base within the context of an independent discussion specific
access challenges facing pharmaceutical manufacturers. In particular, PDCI helps pharmaceutical to your industry. Should you wish to join the increasing number of
companies develop successful pricing and reimbursement strategies and prepare comprehensive companies benefiting from sponsoring our conferences please call:
submissions to CADTH/CDR, INESSS, public & private payers and the Patented Medicine Prices Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk
Review Board (PMPRB). The Canadian market access capabilities are supported by PDCI’s
Want to know how you can get involved?
comprehensive public payer claims database and the industry standard Canadian Drug Benefits Plan
Interested in promoting your pharmaceutical services to this market?
(CDBP) reference guide. PDCI also maintains extensive databases of international pharmaceutical
prices in support of PDCI’s international payer research and global pricing strategy engagements. Contact Kiran Sharma, SMi Marketing on +44 (0)20 7827 6050, or
Headquartered in Ottawa, PDCI features a senior team of bilingual market access professionals with email: ksharma@smi-online.co.uk
extensive pricing and reimbursement experience. www.pdci.ca
4. HALF-DAY POST-CONFERENCE WORKSHOP
Wednesday 2nd November 2011
Radisson Blu Hotel Basel, Basel, Switzerland.
8.30am - 12.30pm
Workshop A
Market Access in Emerging Markets
Overview of growth opportunities
and key market access challenges in
emerging markets.
In association with
Overview of Workshop
IHS Global Insight Country Intelligence provides constantly
updated analysis of the business conditions, economic
prospects and risks in over 200 countries.
Find out about the growth opportunities in emerging markets
including BRIC-MT countries, Philippines, Indonesia, Kenya
and South Africa. Understand the evolution of healthcare
policies and their impact on pricing and reimbursement.
Identify the unique challenges to market access in these
countries in the context of global pricing and reimbursement
trends.
• Monitor and understand developments as economic and
political conditions change
• Assess growth and development potential for individual
economies and regional markets
• Analyze relative risks among countries around the world
Agenda
8.30 Registration and coffee
9.00 Welcome and Introduction
9.10 Emerging Versus Advanced Markets
• Forecasted Outlook in Emerging Versus Advanced
Markets
• Growth Opportunities in Emerging Versus
Advanced Markets
• The Unique Challenges of Emerging Markets
9.50 BRIC-MT Markets Overview
• Best Growth Opportunities in the BRIC-MT Region
10.30 Coffee Break
11.00 Latin America Overview
• P&R Regulations Evolution in Latin America
11.40 The Next Frontier: Second Tier Emerging Markets
• Growth opportunities and challenges in
Philippines, Indonesia, Kenya, South Africa
12.30 Close of workshop
About the Workshop Leaders:
Ruben Gennero is the healthcare analyst for Latin
American markets and Spain. Before joining IHS
Global Insight, Ruben worked at the Chilean
Ministry of Health as a Health Management and
was Policy Advisor for the Chilean health
authorities, participating in healthcare and pharmaceutical
reforms assessments and carrying out different proposals as
project manager. He left the Ministry of Health and worked as
an external advisor of GlaxoSmithkline Chile, focusing on
health policy and market access issues.
Aparna Krishnan is Manager/Senior Research
Analyst at IHS Global Insight’s Healthcare &
Pharma Practice in London in charge of the
practice’s subscription services namely World
Markets Healthcare and Pricing &
Reimbursement. Her areas of expertise includes corporate
strategies, health economics, market access, drug pricing
and reimbursement and generics in the pharmaceutical and
healthcare space.
Gustav Ando leads the Healthcare and Pharma
Practice at IHS. Formerly a healthcare analyst, he
has extensive experience in the fields of market
access, therapeutic development, drug safety,
emerging markets and health outcomes. He has
developed numerous information tools for pharmaceutical
companies and has led consulting projects on global pricing
trends, reference pricing, risk-sharing agreements,
therapeutic-specific market access strategies, bespoke
database creation and internal corporate P&R strategy
benchmarking.
5. HALF-DAY POST-CONFERENCE WORKSHOP
Wednesday 2nd November 2011
Radisson Blu Hotel Basel, Basel, Switzerland.
1.00pm - 5.00pm
Workshop B
Cooperation with Payors as a Means
for Attaining Reimbursement
In association with
Roman Rittweger Advisors in Healthcare
Overview of Workshop
The pricing and reimbursement landscape is increasingly
directed by cost-benefit analyses through government
agencies closely linked to payors' and governments' cost
containment initiatives. In order to convince payors of a
pharmaceutical product's benefit, seeking cooperation
between the pharmaceutical industry and payors is of
utmost importance. In this interactive workshop, we will
work out strategies for approaching the relevant players
of public health systems in order to provide them with
arguments for supporting a product's reimbursement.
“Traditional”cost-saving value added services such as
disease management, targeted patient training or cost-
sharing schemes will be addressed as well as promising
new opportunities from linking smartphone apps to
patient management platforms and to generate
outcomes data from that, e.g. register studies.
This Workshop Will Cover:
• How payors can be motivated to enter pharma
cooperations
• Some current best practice examples and new ideas
• Development and discussion of participants' own ideas
for value added services
Agenda
1.00 Registration & Coffee
1.30 Welcome and introduction
1.40 Reimbursement decision-making in key
European countries
• The pivotal position of public payors
• Challenges for the pharmaceutical industry
• Potential new opportunities
2.10 Interactive work in two-person small teams,
supported by the workshop leader
• Concrete services adding value to products to
be chosen by workshop participants
• Possible strategies for approaching public payors
3.50 Coffee Break
3.50 Presentation and discussion of ideas developed
in the working teams
5.00 End of Workshop
For more information and updates visit the conference
website at www.smi-online.co.uk/2011europricing.asp
About the Workshop Leader:
Norbert Jersch PhD is partner of Roman
Rittweger Advisors in Healthcare. For several
years, THEgained business experience at
ABOUT he SMi PHARMACEUTICAL TEAM
Roche have been where he hadin the
SMi Diagnostics involved developed
the diabetes home monitoring 1993 and He
pharmaceutical industry since market.
became VP of global product planning and
have developed a series of informative and
marketing for the diabetes care product line. Norbert
niche events, covering the latest issues and
Jersch joint and managed two small IT companies which
developed software for documentation and Events
developments surrounding the industry. QM and
bring together senior industry professionals and
provided IT services to physicians. In 2002 he managed
serving companies who have a focus on being at the
4sigma GmbH, an innovative service provider for payors
andforefront of developments in this management. After
a market leader in disease area. SMi aim to
having restructured and topical discussion its daughters
generate informed the company and through the
Norbert Jersch entered into theand executive briefings.
medium of both conferences consulting business. With
his expertise from implementing diabetes care and not
Our pharmaceutical events are research-based and
only diabetes products he became a pioneer in diabetes
content driven with regular contact with major
disease management. He successfully set up excellent
industry personnel and cover a wide range of industry
relations with medical and governmental organizations
sectors. For more information, please visit www.smi-
including IDF and WHO. He was the organizer of the first
World Diabetes Day in 1991. For the last few years he has
online.co.uk/pharma
been working on value added service programs and on
eHealth and IT solutions for Pharma and Medtech
companies.
6. EUROPEAN PHARMACEUTICAL PRICING AND REIMBURSEMENT
Conference: Monday 31st October & Tuesday 1st November 2011, Radisson Blu Hotel Basel, Switzerland Workshop: Wednesday 2nd November 2011, Switzerland
4 WAYS TO REGISTER
www.smi-online.co.uk/2011europricing.asp
FAX your booking form to +44 (0) 870 9090 712 POST your booking form to: Events Team, SMi Group Ltd, Great Guildford
PHONE on +44 (0) 870 9090 711 Business Square, 30 Great Guildford Street London, SE1 0HS, UK
EARLY BIRD □ Book by 30th June to receive £300 off the conference price
DISCOUNT
CONFERENCE PRICES
I would like to attend: (Please tick as appropriate) Fee
□ Conference & Interactive Workshops (A & B) £2597.00
□ Conference & One Interactive Workshop £1998.00
Please indicate which workshop you wish to attend: Workshop A □ Workshop B □
Unique Reference Number
□ Conference only £1399.00
□ Two Half-Day Workshops (A & B) £1198.00
Our Reference LVP-008 □ One Interactive Workshop £599.00
Please indicate which workshop you wish to attend: Workshop A □ Workshop B □
DELEGATE DETAILS PROMOTIONAL LITERATURE DISTRIBUTION
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
Title: Forename:
GROUP DISCOUNTS AVAILABLE
Surname: The conference fee includes refreshments, lunch, conference papers and access
Job Title: to the Document Portal containing all of the presentations.
Department/Division:
Company/Organisation: VENUE Radisson Blu Hotel Basel, Switzerland
Email: □ Please contact me to book my hotel
Address: Alternatively call us on +44 (0) 870 9090 711,
email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712
Town/City:
Post/Zip Code: Country:
DOCUMENTATION
Direct Tel: Direct Fax: I cannot attend but would like to purchase access to the following Document
Portal/paper copy documentation Price Total
Mobile: □ Access to the conference documentation
Switchboard: on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
Signature: Date: (or only £300 if ordered with the Document Portal)
I agree to be bound by SMi's Terms and Conditions of Booking.
ACCOUNTS DEPT PAYMENT
Title: Forename:
Payment must be made to SMi Group Ltd, and received before the event, by one of the
Surname: following methods quoting reference P-008 and the delegate’s name. Bookings made within
7 days of the event require payment on booking, methods of payment are below. Please
Email: indicate method of payment:
Address (if different from above):
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
Town/City:
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
Post/Zip Code: Country: □ Credit Card □ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
Direct Tel: Direct Fax:
Card No: □□□□ □□□□ □□□□ □□□□
Terms and Conditions of Booking Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Payment: If payment is not made at the time of booking, then an invoice will be issued and must be
paid immediately and prior to the start of the event. If payment has not been received then credit card
details will be requested and payment taken before entry to the event. Bookings within 7 days of
event require payment on booking. Access to the Document Portal will not be given until payment
has been received.
Cardholder’s Name:
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate. Signature: Date:
Cancellation: If you wish to cancel your attendance at an event and you are unable to send a I agree to be bound by SMi's Terms and Conditions of Booking.
substitute, then we will refund/credit 50% of the due fee less a £50 administration charge,
providing that cancellation is made in writing and received at least 28 days prior to the start of the Card Billing Address (If different from above):
event. Regretfully cancellation after this time cannot be accepted. We will however provide the
conferences documentation via the Document Portal to any delegate who has paid but is unable to
attend for any reason. Due to the interactive nature of the Briefings we are not normally able to
provide documentation in these circumstances. We cannot accept cancellations of orders placed
for Documentation or the Document Portal as these are reproduced specifically to order. If we have
to cancel the event for any reason, then we will make a full refund immediately, but disclaim any
further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other
VAT
products and services. Unless you tick here □ we may also share your data with third parties VAT at 20% is charged on Document Portal and Literature Distribution for all UK customers and for
offering complementary products or services. If you have any queries or want to update any of the
data that we hold then please contact our Database Manager databasemanager@smi-online.co.uk those EU customers not supplying a registration number for their own country here:
or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your
address on the attached letter. ____________________________________________________________________________
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk